Iovance Biotherapeutics: Initial Amtagvi Launch In Focus [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Initial numbers from the early days of the launch can be considered when trying to project revenues from Amtagvi going forward. IOVA can improve potential revenues by gaining approval of its TIL therapies like Amtagvi outside of the US and in new indications. In the short term, however, the focus may be on the current Amtagvi launch, where some success may already be reflected in the price. I wrote about Iovance Biotherapeutics ( NASDAQ: IOVA ) in December, rating it a buy, as I thought approval of their tumor-infiltrating lymphocyte (TIL) product, lifileucel, for the treatment of advanced melanoma was likely. This February, Lifileucel (marketed as Amtagvi) was indeed approved by the Food and Drug Administration (FDA). This article takes a look at what we can garner from the initial comments made by the company on the launch, and why I now rate IOVA a hold. Initial Amtagvi demand may be high While Amtagvi was only approved in the US on February 16, by the time of Q4'23 earn
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- 3 Millionaire-Maker Biotech Stocks [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingGlobeNewswire
- These Biotech Stocks Could Soar 120% and 295%, According to Wall Street [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Is Iovance Biotherapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- IOVA's page on the SEC website